Used primarily in biomedical research, 5-Iodo-indirubin-3'-monoxime is a potent dual inhibitor of glycogen synthase kinase-3 (GSK-3, particularly GSK-3β) and cyclin-dependent kinases (CDKs). It is extensively studied for its potential in treating neurodegenerative diseases, such as Alzheimer's, by modulating tau protein phosphorylation. Additionally, it shows promise in cancer research due to its ability to induce apoptosis and inhibit cell proliferation in various cancer cell lines. Its application extends to studying Wnt signaling pathways, which are crucial in developmental biology and cellular processes. The compound is also explored for its anti-inflammatory properties, making it a candidate for therapeutic interventions in inflammatory diseases.